RACHEL LITTERER: Open Payments
NPI 1740500214 · HORN LAKE, MS. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,336 in 75 payments from 20 companies in 2025. Trend: 2023 $0 · 2024 $25 · 2025 $1,336
Food & beverage: $1,336
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 12 | $210 |
| Bayer Healthcare Pharmaceuticals Inc. | 8 | $175 |
| Amgen Inc. | 12 | $137 |
| Sumitomo Pharma America, Inc. | 6 | $116 |
| ABBVIE INC. | 5 | $109 |
| Novo Nordisk Inc | 6 | $103 |
| Lilly USA, LLC | 6 | $95 |
| Esperion Therapeutics, Inc. | 3 | $61 |
| IBSA Pharma Inc. | 3 | $50 |
| Dexcom, Inc. | 2 | $49 |
Products named: FARXIGA, Kerendia, GEMTESA, UBRELVY, OTEZLA, NEXLETOL, REPATHA, Ozempic.
Industry payments across MS — which companies pay providers there.
